Hormones and homocysteine.

S. Asnani, Cyrus V Desouza, J. Homan, S. N. Murthy, D. B. McNamara, V. Fonseca

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Hyperhomocysteinemia is a well-established risk factor for cardiovascular disease. Various factors, both modifiable and non-modifiable, interact with the homocysteine metabolism and determine the plasma homocysteine concentrations. These include genetic abnormalities, age, sex and various nutritional and hormonal determinants, all of which play a role in atherosclerosis and accelerated peripheral and cardio-vascular disease (CVD). Several hormones modulate homocysteine metabolism and hence may play a role in the pathogenesis of CVD. The mechanisms involved are unclear. The association of hyperhomocysteinemia with diabetes mellitus is complex and may explain some of the risk of CVD in diabetics not explained by traditional risk factors. Much conflicting data exists in the literature on the role of insulin on homocysteine metabolism, although insulin affects the enzymes regulating the homocysteine metabolism. Treatment of hyperhomocysteinemia with vitamins lowers plasma homocysteine concentrations. Little data is available on the effect of this intervention on cardiovascular outcomes. This review briefly outlines the homocysteine metabolism, summarizes its hormonal determinants, and discusses the role of hyperhomocysteinemia in diabetes, hyperlipidemia and other endocrine disorders.

Original languageEnglish (US)
Pages (from-to)141-155
Number of pages15
JournalMinerva endocrinologica
Volume27
Issue number3
StatePublished - Jan 1 2002

Fingerprint

Homocysteine
Hormones
Hyperhomocysteinemia
Insulin
Diabetic Angiopathies
Peripheral Vascular Diseases
Hyperlipidemias
Vascular Diseases
Vitamins
Atherosclerosis
Diabetes Mellitus
Cardiovascular Diseases
Enzymes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Asnani, S., Desouza, C. V., Homan, J., Murthy, S. N., McNamara, D. B., & Fonseca, V. (2002). Hormones and homocysteine. Minerva endocrinologica, 27(3), 141-155.

Hormones and homocysteine. / Asnani, S.; Desouza, Cyrus V; Homan, J.; Murthy, S. N.; McNamara, D. B.; Fonseca, V.

In: Minerva endocrinologica, Vol. 27, No. 3, 01.01.2002, p. 141-155.

Research output: Contribution to journalReview article

Asnani, S, Desouza, CV, Homan, J, Murthy, SN, McNamara, DB & Fonseca, V 2002, 'Hormones and homocysteine.', Minerva endocrinologica, vol. 27, no. 3, pp. 141-155.
Asnani S, Desouza CV, Homan J, Murthy SN, McNamara DB, Fonseca V. Hormones and homocysteine. Minerva endocrinologica. 2002 Jan 1;27(3):141-155.
Asnani, S. ; Desouza, Cyrus V ; Homan, J. ; Murthy, S. N. ; McNamara, D. B. ; Fonseca, V. / Hormones and homocysteine. In: Minerva endocrinologica. 2002 ; Vol. 27, No. 3. pp. 141-155.
@article{efec5d23a4444ad280fd4094c59b02ad,
title = "Hormones and homocysteine.",
abstract = "Hyperhomocysteinemia is a well-established risk factor for cardiovascular disease. Various factors, both modifiable and non-modifiable, interact with the homocysteine metabolism and determine the plasma homocysteine concentrations. These include genetic abnormalities, age, sex and various nutritional and hormonal determinants, all of which play a role in atherosclerosis and accelerated peripheral and cardio-vascular disease (CVD). Several hormones modulate homocysteine metabolism and hence may play a role in the pathogenesis of CVD. The mechanisms involved are unclear. The association of hyperhomocysteinemia with diabetes mellitus is complex and may explain some of the risk of CVD in diabetics not explained by traditional risk factors. Much conflicting data exists in the literature on the role of insulin on homocysteine metabolism, although insulin affects the enzymes regulating the homocysteine metabolism. Treatment of hyperhomocysteinemia with vitamins lowers plasma homocysteine concentrations. Little data is available on the effect of this intervention on cardiovascular outcomes. This review briefly outlines the homocysteine metabolism, summarizes its hormonal determinants, and discusses the role of hyperhomocysteinemia in diabetes, hyperlipidemia and other endocrine disorders.",
author = "S. Asnani and Desouza, {Cyrus V} and J. Homan and Murthy, {S. N.} and McNamara, {D. B.} and V. Fonseca",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "27",
pages = "141--155",
journal = "Minerva Endocrinologica",
issn = "0391-1977",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

TY - JOUR

T1 - Hormones and homocysteine.

AU - Asnani, S.

AU - Desouza, Cyrus V

AU - Homan, J.

AU - Murthy, S. N.

AU - McNamara, D. B.

AU - Fonseca, V.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Hyperhomocysteinemia is a well-established risk factor for cardiovascular disease. Various factors, both modifiable and non-modifiable, interact with the homocysteine metabolism and determine the plasma homocysteine concentrations. These include genetic abnormalities, age, sex and various nutritional and hormonal determinants, all of which play a role in atherosclerosis and accelerated peripheral and cardio-vascular disease (CVD). Several hormones modulate homocysteine metabolism and hence may play a role in the pathogenesis of CVD. The mechanisms involved are unclear. The association of hyperhomocysteinemia with diabetes mellitus is complex and may explain some of the risk of CVD in diabetics not explained by traditional risk factors. Much conflicting data exists in the literature on the role of insulin on homocysteine metabolism, although insulin affects the enzymes regulating the homocysteine metabolism. Treatment of hyperhomocysteinemia with vitamins lowers plasma homocysteine concentrations. Little data is available on the effect of this intervention on cardiovascular outcomes. This review briefly outlines the homocysteine metabolism, summarizes its hormonal determinants, and discusses the role of hyperhomocysteinemia in diabetes, hyperlipidemia and other endocrine disorders.

AB - Hyperhomocysteinemia is a well-established risk factor for cardiovascular disease. Various factors, both modifiable and non-modifiable, interact with the homocysteine metabolism and determine the plasma homocysteine concentrations. These include genetic abnormalities, age, sex and various nutritional and hormonal determinants, all of which play a role in atherosclerosis and accelerated peripheral and cardio-vascular disease (CVD). Several hormones modulate homocysteine metabolism and hence may play a role in the pathogenesis of CVD. The mechanisms involved are unclear. The association of hyperhomocysteinemia with diabetes mellitus is complex and may explain some of the risk of CVD in diabetics not explained by traditional risk factors. Much conflicting data exists in the literature on the role of insulin on homocysteine metabolism, although insulin affects the enzymes regulating the homocysteine metabolism. Treatment of hyperhomocysteinemia with vitamins lowers plasma homocysteine concentrations. Little data is available on the effect of this intervention on cardiovascular outcomes. This review briefly outlines the homocysteine metabolism, summarizes its hormonal determinants, and discusses the role of hyperhomocysteinemia in diabetes, hyperlipidemia and other endocrine disorders.

UR - http://www.scopus.com/inward/record.url?scp=0036729539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036729539&partnerID=8YFLogxK

M3 - Review article

VL - 27

SP - 141

EP - 155

JO - Minerva Endocrinologica

JF - Minerva Endocrinologica

SN - 0391-1977

IS - 3

ER -